6 results · Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary DiseaseChronic Disease, Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, chronic obstructive pulmonary disease, lung disorder, obstructive lung disease, respiratory system disorderRecruitingPhase 32026-10-02NCT06283966
Real-world Effectiveness Study of Long-term Treatment With Dupilumab in Participants ≥6 Years With Atopic DermatitisCongenital, Hereditary, and Neonatal Diseases and Abnormalities, Hypersensitivity, Immediate, Skin Diseases, Eczematous, Skin and Connective Tissue Diseases, atopic eczema, dermatitis, hereditary disease, hereditary skin disorder, immune system disorder, skin disorderActive, not recruitingNot stated2026-09-24NCT06039241
A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary DiseaseChronic Disease, Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, chronic obstructive pulmonary disease, lung disorder, obstructive lung disease, respiratory system disorderRecruitingPhase 22026-09-09NCT07082738
A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)Chronic Disease, Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, chronic obstructive pulmonary disease, lung disorder, obstructive lung disease, respiratory system disorderActive, not recruitingPhase 32026-08-14NCT05878769
A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal PolypsChronic Rhinosinusitis With Nasal PolypsActive, not recruitingPhase 32026-05-20NCT06834347
Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA TreatmentEosinophilia, Hemic and Lymphatic Diseases, hematologic disorder, hypereosinophilic syndrome, leukocyte disorder, lung disorder, pulmonary eosinophilia, respiratory system disorderRecruitingPhase 32026-05-13NCT06750289